Comparison of different IVIg preparations on IL-17 production by human Th17 cells

Autoimmunity Reviews

Volumn 10, Issue 12, 2011, Pages 809-810

  Maddur, Mohan S ^a,b,c   Kaveri, Srini V ^a,b,c   Bayry, Jagadeesh ^a,b,c,d  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 17; TAGELINE; UNCLASSIFIED DRUG;

ALLERGY; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; HUMAN; IMMUNOREGULATION; LETTER; PROTEIN FUNCTION; TH17 CELL;

CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; TH17 CELLS;

EID: 80053231181     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.02.007     Document Type: Letter

References (20)

1. Tha-In T., Bayry J., Metselaar H.J., Kaveri S.V., Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008, 29:608-615.
2. Seite J.F., Shoenfeld Y., Youinou P., Hillion S. What is the contents of the magic draft IVIg?. Autoimmun Rev 2008, 7:435-439.
3. Danieli M.G., Calcabrini L., Calabrese V., Marchetti A., Logullo F., Gabrielli A. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 2009, 9:124-127.
4. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26:513-533.
5. Kaveri S.V., Lacroix-Desmazes S., Bayry J. The antiinflammatory IgG. N Engl J Med 2008, 17(359):307-309.
6. Schwartz-Albiez R., Monteiro R.C., Rodriguez M., Binder C.J., Shoenfeld Y. Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol 2009, 158(Suppl. 1):43-50.
7. Gurcan H.M., Keskin D.B., Ahmed A.R. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev 2010, 9:553-559.
8. Krause I., Wu R., Sherer Y., Patanik M., Peter J.B., Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations-a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 2002, 12:133-139.
9. Roifman C.M., Schroeder H., Berger M., Sorensen R., Ballow M., Buckley R.H., et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003, 3:1325-1333.
10. Gelfand E.W. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006 Apr, 6:592-599.
11. Louten J., Boniface K., de Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol 2009, 123:1004-1011.
12. Annunziato F., Cosmi L., Liotta F., Maggi E., Romagnani S. Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 2009, 5:325-331.
13. Yang K., Vega J.L., Hadzipasic M., Schatzmann Peron J.P., Zhu B., Carrier Y., et al. Deficiency of thrombospondin-1 reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitis. J Autoimmun 2009, 32:94-103.
14. Mucida D., Salek-Ardakani S. Regulation of TH17 cells in the mucosal surfaces. J Allergy Clin Immunol 2009, 123:997-1003.
15. Lan R.Y., Salunga T.L., Tsuneyama K., Lian Z.X., Yang G.X., Hsu W., et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 2009, 32:43-51.
16. Selmi C. Autoimmunity in 2009. Autoimmun Rev 2010, 9:795-800.
17. Baraut J., Michel L., Verrecchia F., Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010, 10:65-73.
18. Galeotti C., Bayry J., Kone-Paut I., Kaveri S.V. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev 2010, 9:441-448.
19. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011, 127:315-323.
20. Maddur M.S., Vani J., Hegde P., Lacroix-Desmazes S., Kaveri S.V., Bayry J. Inhibition of differentiation, amplification and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 2011, 127:823-830.e7.